MCID: CRV043
MIFTS: 45

Cervical Dystonia

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Cervical Dystonia

MalaCards integrated aliases for Cervical Dystonia:

Name: Cervical Dystonia 12 49 36 14
Spasmodic Torticollis 12 72 49

Classifications:



External Ids:

Disease Ontology 12 DOID:0050840
KEGG 36 H01608
ICD10 32 G24.3

Summaries for Cervical Dystonia

NIH Rare Diseases : 49 Cervical dystoniais a neurological condition characterized by excessive pulling of the muscles of the neck and shoulder resulting in abnormal movements of the head (dystonia). Most commonly, the head turns to one side or the other. Tilting sideways, or to the back or front may also occur. The turning or tilting movements may be accompanied by shaking movement (tremor) and/or soreness of the muscles of the neck and shoulders. Cervical dystonia can occur at any age, but most cases occur in middle age. It often begins slowly and usually reaches a plateau over a few months or years. The cause of cervical dystonia is often unknown. In some cases there is a family history. Several genes have been associated with cervical dystonia, including GNAL, THAP1, CIZ1, and ANO3. Other cases may be linked to an underlying disease (e.g. Parkinson disease), neck trauma, or certain medications. Treatment may include local injections of botulinum toxin, pain medications, benzodiazepines (anti-anxiety medications), anticholinergics, physical therapy, or surgery. Last updated: 11/30/2016

MalaCards based summary : Cervical Dystonia, also known as spasmodic torticollis, is related to dystonia 11, myoclonic and torticollis. An important gene associated with Cervical Dystonia is CIZ1 (CDKN1A Interacting Zinc Finger Protein 1), and among its related pathways/superpathways are ICos-ICosL Pathway in T-Helper Cell and Tuberculosis. The drugs Acetylcholine and Menthol have been mentioned in the context of this disorder. Affiliated tissues include brain, cerebellum and testes, and related phenotype is behavior/neurological.

Disease Ontology : 12 A focal dystonia that is characterized by simultaneous contraction of the agonist and antagonist muscles that control the position of the head contracting during dystonic movement which causes the neck to involuntarily turn to the left, right, upwards, and/or downwards.

Wikipedia : 72 Spasmodic torticollis is an extremely painful chronic neurological movement disorder causing the neck to... more...

Related Diseases for Cervical Dystonia

Diseases related to Cervical Dystonia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 97)
# Related Disease Score Top Affiliating Genes
1 dystonia 11, myoclonic 30.9 CAMP GCH1 TOR1A
2 torticollis 30.6 CIZ1 TOR1A
3 dystonia 30.4 CIZ1 DRD5 GCH1 GNAL TOR1A
4 focal hand dystonia 29.0 CAMP DRD5 TOR1A
5 blepharospasm 28.8 CAMP DRD5 GCH1 GNAL TOR1A
6 spasmodic dystonia 28.8 CAMP GNAL TOR1A
7 focal dystonia 28.3 CAMP CIZ1 DRD5 GNAL TOR1A
8 lymphedema, hereditary, ii 28.3 CAMP DRD5 GCH1 TOR1A
9 dystonia 23 11.6
10 leukoencephalopathy with dystonia and motor neuropathy 11.3
11 dystonia 7, torsion 11.3
12 torticollis, familial 11.2
13 x-linked dystonia-parkinsonism/lubag 11.1
14 cervicitis 11.1
15 dystonia 24 11.0
16 dystonia 4, torsion, autosomal dominant 10.9
17 torsion dystonia 4 10.9
18 adolescent-onset dystonia of mixed type 10.9
19 tremor 10.3
20 achalasia, familial esophageal 10.3 HLA-DQA1 HLA-DQB1
21 focal epithelial hyperplasia 10.3 HLA-DQA1 HLA-DQB1
22 beryllium disease 10.3 HLA-DQA1 HLA-DQB1
23 recurrent respiratory papillomatosis 10.2 HLA-DQA1 HLA-DQB1
24 congenital toxoplasmosis 10.2 HLA-DQA1 HLA-DQB1
25 acute disseminated encephalomyelitis 10.2 HLA-DQA1 HLA-DQB1
26 episodic pain syndrome, familial, 1 10.2
27 idiopathic bronchiectasis 10.2 HLA-DQA1 HLA-DQB1
28 oligoarticular juvenile idiopathic arthritis 10.2 HLA-DQA1 HLA-DQB1
29 endometritis 10.2 HLA-DQA1 HLA-DQB1
30 immunoglobulin alpha deficiency 10.1 HLA-DQB1 TOR1A
31 ataxia and polyneuropathy, adult-onset 10.1
32 essential tremor 10.1
33 autosomal dominant cerebellar ataxia 10.0
34 kleine-levin hibernation syndrome 10.0 HLA-DQB1 TOR1A
35 early-onset generalized dystonia 10.0 GCH1 TOR1A
36 headache 10.0
37 thiamine metabolism dysfunction syndrome 2 10.0 GCH1 TOR1A
38 autoimmune disease of gastrointestinal tract 10.0 HLA-DQA1 TOR1A
39 aging 10.0
40 laryngitis 10.0
41 hemifacial spasm 10.0
42 leukodystrophy, hypomyelinating, 2 9.9 GCH1 TOR1A
43 celiac disease 1 9.9 HLA-DQA1 HLA-DQB1 TOR1A
44 multifocal dystonia 9.9 CAMP TOR1A
45 spinocerebellar ataxia 2 9.9
46 acute cervicitis 9.9
47 cerebritis 9.9
48 dysphagia 9.9
49 spasticity 9.9
50 brachial plexus lesion 9.9 BDNF CAMP

Graphical network of the top 20 diseases related to Cervical Dystonia:



Diseases related to Cervical Dystonia

Symptoms & Phenotypes for Cervical Dystonia

MGI Mouse Phenotypes related to Cervical Dystonia:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.17 BDNF CIZ1 DRD5 GNAL HLA-DQB1 NALCN

Drugs & Therapeutics for Cervical Dystonia

Drugs for Cervical Dystonia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-84-3 187
2
Menthol Approved Phase 4 2216-51-5 16666
3 abobotulinumtoxinA Phase 4,Phase 3,Phase 1,Phase 2
4 Botulinum Toxins Phase 4,Phase 3,Phase 2,Phase 1
5 Botulinum Toxins, Type A Phase 4,Phase 3,Phase 1,Phase 2
6 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Neuromuscular Agents Phase 4,Phase 3,Phase 1,Phase 2
8 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
9 onabotulinumtoxinA Phase 4,Phase 3,Phase 1,Phase 2
10 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
12 rimabotulinumtoxinB Phase 4,Phase 2
13 incobotulinumtoxinA Phase 4,Phase 3,Phase 2
14
Dronabinol Approved, Illicit Phase 2 1972-08-3 16078 2978
15
Etanercept Approved, Investigational Phase 1, Phase 2 185243-69-0
16
Amlodipine Approved Phase 2 88150-42-9 2162
17 Etiracetam Investigational Phase 2 33996-58-6
18 Analgesics Phase 2,Phase 1
19 Analgesics, Non-Narcotic Phase 2,Phase 1
20 Cannabinoid Receptor Agonists Phase 2
21 Hallucinogens Phase 2
22 Hormone Antagonists Phase 2
23 Hormones Phase 2
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
25 Psychotropic Drugs Phase 2
26 Anti-Inflammatory Agents Phase 1, Phase 2
27 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
28 Antirheumatic Agents Phase 1, Phase 2
29 Autoantibodies Phase 1, Phase 2
30 Gastrointestinal Agents Phase 1, Phase 2
31 Immunosuppressive Agents Phase 1, Phase 2
32 Antihypertensive Agents Phase 2
33 calcium channel blockers Phase 2
34 Calcium, Dietary Phase 2
35 Vasodilator Agents Phase 2
36 Anticonvulsants Phase 2
37 Nootropic Agents Phase 2
38
Trihexyphenidyl Approved 144-11-6, 58947-95-8 5572
39
Triamcinolone Approved, Vet_approved 124-94-7 31307
40
Cortisone acetate Approved, Investigational 1950-04-4, 50-04-4 5745
41
Methylprednisolone Approved, Vet_approved 83-43-2 6741
42
Prednisolone Approved, Vet_approved 50-24-8 5755
43 Antiparkinson Agents
44 Cholinergic Antagonists
45 Muscarinic Antagonists
46 triamcinolone acetonide
47 Triamcinolone diacetate
48 Triamcinolone hexacetonide
49 Dihydroxyphenylalanine
50 Antipruritics

Interventional clinical trials:

(show top 50) (show all 97)

# Name Status NCT ID Phase Drugs
1 The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients Unknown status NCT01664013 Phase 4 Nuronox
2 Botox for Cervical Dystonia Following EMG Mapping Completed NCT00773253 Phase 4 Botulinum toxin A
3 An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution in Patients With Cervical Dystonia Completed NCT00702754 Phase 4
4 A Study to Compare Dysport® and Botox® in the Treatment of Cervical Dystonia Completed NCT00950664 Phase 4 Dysport® (abobotulinumtoxinA);Botox® (onabotulinumtoxinA)
5 Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex Completed NCT01486264 Phase 4
6 Daily Dystonia Practice - A Trial to Investigate NT 201, the Duration of Treatment Effect After One Injection Session and in Long-term Treatment in Cervical Dystonia Completed NCT00541905 Phase 4 NT 201
7 A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm Completed NCT02245958 Phase 4
8 Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy Completed NCT01860196 Phase 4 Meditoxin;Normal saline
9 Neurotoxin and Physical Therapy Completed NCT02177617 Phase 4 Botox injection
10 Effect of Botulinum Toxin Type A on Swallowing in Patients With Cervical Dystonia Completed NCT01384214 Phase 4
11 Comparison of Efficacy and Safety of Two Different Types of Botulinum Toxin Type A in Moderate to Severe Cervical Dystonia Completed NCT00528541 Phase 4
12 Functional Effects of Botox on the Brain Using MRS and fMRI Completed NCT03373162 Phase 4 onabotulinumtoxinA
13 Post Marketing Surveillance Study of Dysport Completed NCT00210431 Phase 4
14 OnabotulinumtoxinA in the Management of Psychogenic Dystonia Recruiting NCT02618889 Phase 4
15 Frontalis Botulinum Toxin Not yet recruiting NCT03186001 Phase 4 Abobotulinum toxin A
16 Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Moderate to Severe Cervical Dystonia Terminated NCT00432341 Phase 4
17 Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia Completed NCT00447772 Phase 3 Botulinum type A toxin (Dysport®)
18 Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia. Completed NCT01753310 Phase 3 Dysport®;Placebo
19 Study Comparing Short Term Efficacy of Dysport® and Dysport RU® to Placebo, and to Assess Efficacy and Safety of Dysport RU® of Subjects With Cervical Dystonia Completed NCT01261611 Phase 3 Botulinum type A toxin (Dysport RU®);Botulinum type A toxin (Dysport®);Placebo
20 Double-blind, Multicenter Study to Assess the Efficacy of Bilateral Pallidal Stimulation in Patients With Medically Refractory Primary Cervical Dystonia Completed NCT00148889 Phase 3
21 Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia Completed NCT01753336 Phase 3 Dysport®
22 Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia Completed NCT00288509 Phase 3 abobotulinumtoxinA (Dysport) 250-1000 units
23 Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia Completed NCT00257660 Phase 3 Botulinum type A toxin (Dysport®);Placebo
24 IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia Completed NCT00407030 Phase 3 incobotulinumtoxinA (Xeomin) (240 Units);incobotulinumtoxinA (Xeomin) (120 Units);Placebo
25 Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia Completed NCT02604186 Phase 2, Phase 3
26 Meditoxin® Treatment in Patients With Cervical Dystonia Recruiting NCT03232320 Phase 3 Meditoxin;Placebo
27 Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor Recruiting NCT02555982 Phase 3 BOTOX ® 200 Unités;Placebo
28 Efficacy of Dronabinol for the Treatment of Cervical Dystonia Unknown status NCT00418925 Phase 2 Dronabinol
29 ASIS for Botox in Cervical Dystonia Unknown status NCT02074293 Phase 1, Phase 2 Gadolinium;Gadolinium;Gadolinium;Efficacy of Botox intramuscularly at Week 6;Efficacy of Botox intramuscularly at Week 12;Efficacy of Botox intramuscularly at Week 18;Efficacy of Botox intramuscularly at Week 24;Efficacy of Botox intramuscularly at Week 30;Efficacy of Botox subdermally at Week 6;Efficacy of Botox subdermally at Week 12;Efficacy of Botox subdermally at Week 18;Efficacy of Botox subdermally at Week 24;Efficacy of Botox subdermally at Week 30;Adverse Reactions of Botox intramuscularly;Adverse Reactions of Botox subdermally
30 ASIS for Enbrel in Plaque Psoriasis Unknown status NCT02112097 Phase 1, Phase 2 Gadolinium;Gadolinium;Gadolinium;Efficacy of Enbrel subcutaneously at Week 12;Efficacy of Enbrel subcutaneously at Week 24;Efficacy of Enbrel subcutaneously at Week 36;Efficacy of Enbrel subdermally at Week 12;Efficacy of Enbrel subdermally at Week 24;Efficacy of Enbrel subdermally at Week 36;PASI 75 n(%) subcutaneously at Week 12;PASI 75 n(%) subcutaneously at Week 24;PASI 75 n(%) subcutaneously at Week 36;PASI 75 n(%) subdermally at Week 12;PASI 75 n(%) subdermally at Week 24;PASI 75 n(%) subdermally at Week 36;Adverse Reactions of Enbrel subcutaneously;Adverse Reactions of Enbrel subdermally at Week 36;Gadolinium;Gadolinium;Gadolinium
31 Botulinum Toxin Type A (Botox) for the Treatment of Cervical Dystonia and Upper Thoracic Muscular Pain Completed NCT00178945 Phase 1, Phase 2 Botulinum Toxin Type A
32 Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia Completed NCT00564681 Phase 2 Normal Saline
33 Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic Torticollis Completed NCT00165776 Phase 2 BOTULINUM TOXIN TYPE B
34 Study for Determine the Safety and Efficacy of Clostridium Botulinum Toxin Type A in Subjects With Cervical Dystonia Completed NCT01588574 Phase 2
35 Amlodipine Plus Botulinum Toxin for Focal Dystonia Completed NCT00015457 Phase 2 Amlodipine plus Botulinum toxin
36 Deep Brain Stimulation for Cervical Dystonia Completed NCT00105430 Phase 2
37 An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian Subjects Completed NCT00280384 Phase 2 E2014 (Botulinum toxin type B);E2014 (Botulinum toxin type B) Placebo
38 Deep Brain Stimulation in Patients With Dystonia Completed NCT00773604 Phase 1, Phase 2
39 Clinical and Kinematic Assessment for Determination of Botox® Injection Parameters in Cervical Dystonia Recruiting NCT02662530 Phase 2 Botulinum Toxin Type A
40 Safety and Tolerability of Perampanel in Cervical Dystonia Recruiting NCT02131467 Phase 1, Phase 2 Perampanel
41 Study of the Treatment of Tendinopathy Unruptured of Rotator Cuff by Intramuscular Injection of Botulinum Toxin Recruiting NCT02867787 Phase 2 Botox arm
42 Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia Active, not recruiting NCT02706795 Phase 2
43 Keppra for Cervical Dystonia Suspended NCT00760318 Phase 2 Keppra
44 Botulinum Toxin Injection Efficiency Unknown status NCT01041157 Phase 1
45 PurTox (Botulinum Toxin Type A) for the Treatment of Adult Onset Spasmodic Torticollis/Cervical Dystonia Completed NCT00549341 Phase 1 Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin
46 Deep Brain Stimulation to Treat Cervical Dystonia Completed NCT00132340 Phase 1
47 A Multicenter Pilot Study of Pallidal Deep Brain Stimulation for Cervical Dystonia Unknown status NCT00132990
48 Clinical Trial of STN-DBS for Primary Cranial-Cervical Dystonia Unknown status NCT02583074
49 Imaging Blood Brain Imaging Dysfunction in Parkinson's Disease Unknown status NCT02605161
50 Validation of the Implantation of a New Electrode for the Treatment of Dystonia Unknown status NCT02509338

Search NIH Clinical Center for Cervical Dystonia

Genetic Tests for Cervical Dystonia

Anatomical Context for Cervical Dystonia

MalaCards organs/tissues related to Cervical Dystonia:

38
Brain, Cerebellum, Testes, Globus Pallidus, Cortex, Subthalamic Nucleus, T Cells

Publications for Cervical Dystonia

Articles related to Cervical Dystonia:

(show top 50) (show all 641)
# Title Authors Year
1
Physiological effects of subthalamic nucleus deep brain stimulation surgery in cervical dystonia. ( 29326293 )
2018
2
Sertraline induced cervical dystonia in a patient of Obsessive Compulsive Disorder. ( 29447992 )
2018
3
Postural control and the relation with cervical sensorimotor control in patients with idiopathic adult-onset cervical dystonia. ( 29340715 )
2018
4
A 500A U/2A mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia. ( 29343142 )
2018
5
Randomised controlled trial of escitalopram for cervical dystonia with dystonic jerks/tremor. ( 29326295 )
2018
6
Abnormal cerebellar processing of the neck proprioceptive information drives dysfunctions in cervical dystonia. ( 29396401 )
2018
7
Measurement & Analysis of the Temporal Discrimination Threshold Applied to Cervical Dystonia. ( 29443021 )
2018
8
Speech induced cervical dystonia: An unusual task specific dystonia. ( 29174183 )
2018
9
The premotor syndrome of cervical dystonia: Disordered processing of salient environmental stimuli. ( 29205495 )
2018
10
INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin. ( 29270685 )
2018
11
Sonographic Guide for Botulinum Toxin Injections of the Neck Muscles in Cervical Dystonia. ( 29173657 )
2018
12
Modulation of the muscle activity during sleep in cervical dystonia. ( 28525628 )
2017
13
Evaluation of the Edrophonium Challenge Test for Cervical Dystonia. ( 28824069 )
2017
14
Alterations of resting-state fMRI measurements in individuals with cervical dystonia. ( 28504361 )
2017
15
Adaptation of feedforward movement control is abnormal in patients with cervical dystonia and tremor. ( 28943258 )
2017
16
Long-Term Abobotulinumtoxin A Treatment of Cervical Dystonia. ( 28478527 )
2017
17
Cervical sensorimotor control in idiopathic cervical dystonia: AA cross-sectional study. ( 28948067 )
2017
18
The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule. ( 28891721 )
2017
19
Ultrasound imaging and guidance in the management of cervical dystonia: A caveat on the compartmentalization of sternocleidomastoid muscle. ( 28851563 )
2017
20
Nonmotor symptoms in primary adult-onset cervical dystonia and blepharospasm. ( 28239516 )
2017
21
Botulinum toxin type A therapy for cervical dystonia. ( 29230798 )
2017
22
Interoceptive sensitivity in patients with cervical dystonia. ( 28827008 )
2017
23
Reply: Contributions of visual and motor signals in cervical dystonia. ( 27993889 )
2017
24
Measuring Disability in Patients With Cervical Dystonia According to the International Classification of Functioning, Disability and Health. ( 28621218 )
2017
25
Cervical dystonia patients display subclinical gait changes. ( 28712731 )
2017
26
A localized pallidal physiomarker in cervical dystonia. ( 29130551 )
2017
27
Expanding the phenotype of phosphomannomutase-2 gene congenital disorder of glycosylation: Cervical dystonia. ( 28566178 )
2017
28
Functional activity of the sensorimotor cortex and cerebellum relates to cervical dystonia symptoms. ( 28594097 )
2017
29
Providing an imputation algorithm for missing values of longitudinal data using Cuckoo search algorithm: A case study on cervical dystonia. ( 28848643 )
2017
30
Disrupted superior collicular activity may reveal cervical dystonia disease pathomechanisms. ( 29196716 )
2017
31
Treatment satisfaction with botulinum toxin: a comparison between blepharospasm and cervical dystonia. ( 29066869 )
2017
32
Endophenotyping in idiopathic adult onset cervical dystonia. ( 28511126 )
2017
33
Spectral EMG Changes in Cervical Dystonia Patients and the Influence of Botulinum Toxin Treatment. ( 28832550 )
2017
34
Cortical inhibitory function in cervical dystonia. ( 29311009 )
2017
35
Biased Visuospatial Attention in Cervical Dystonia. ( 28791940 )
2017
36
Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy? ( 28888929 )
2017
37
Sensory tricks in primary blepharospasm and idiopathic cervical dystonia. ( 28488615 )
2017
38
The influence of occlusal stabilization appliances on cervical dystonia symptoms. ( 29151795 )
2017
39
Botulinumtoxin Improves both Generic and Disease-Specific Quality of Life in Cervical Dystonia. ( 29114239 )
2017
40
The occurrence of lateral shift in cervical dystonia. ( 28054172 )
2017
41
Acute Cervical Dystonia Induced by Clebopride. ( 29333306 )
2017
42
Ixcellence NetworkAr: an international educational network to improve current practice in the management of cervical dystonia or spastic paresis by botulinum toxin injection. ( 28676144 )
2017
43
Contributions of visual and motor signals in cervical dystonia. ( 27993890 )
2017
44
The Effect of Botulinum Toxin on Network Connectivity in Cervical Dystonia: Lessons from Magnetoencephalography. ( 29204314 )
2017
45
Anatomy and cervical dystonia : "Dysfunction follows form". ( 27624726 )
2016
46
Cervical dystonia: a neural integrator disorder. ( 27324878 )
2016
47
The role of polymyography in the treatment of cervical dystonia: the authors reply. ( 27393115 )
2016
48
Cervical dystonia and quality of life. ( 27138215 )
2016
49
Impact of Neu-botulinumtoxinA on the Severity and Quality of Life of Cervical Dystonia Patients. ( 27536464 )
2016
50
Unmet Needs in the Management of Cervical Dystonia. ( 27733842 )
2016

Variations for Cervical Dystonia

Expression for Cervical Dystonia

Search GEO for disease gene expression data for Cervical Dystonia.

Pathways for Cervical Dystonia

Pathways related to Cervical Dystonia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.81 GNAL HLA-DQA1 HLA-DQB1
2 11.38 CAMP HLA-DQA1 HLA-DQB1
3
Show member pathways
11.11 HLA-DQA1 HLA-DQB1
4 10.65 GNAL HLA-DQA1 HLA-DQB1

GO Terms for Cervical Dystonia

Cellular components related to Cervical Dystonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transport vesicle membrane GO:0030658 9.26 HLA-DQA1 HLA-DQB1
2 clathrin-coated endocytic vesicle membrane GO:0030669 9.16 HLA-DQA1 HLA-DQB1
3 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.96 HLA-DQA1 HLA-DQB1
4 MHC class II protein complex GO:0042613 8.62 HLA-DQA1 HLA-DQB1

Biological processes related to Cervical Dystonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 antigen processing and presentation GO:0019882 9.37 HLA-DQA1 HLA-DQB1
2 activation of adenylate cyclase activity GO:0007190 9.32 DRD5 GNAL
3 negative regulation of blood pressure GO:0045776 9.26 DRD5 GCH1
4 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.16 HLA-DQA1 HLA-DQB1
5 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 8.96 DRD5 GNAL
6 regulation of protein localization to cell surface GO:2000008 8.62 BDNF TOR1A

Molecular functions related to Cervical Dystonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 8.96 HLA-DQA1 HLA-DQB1
2 MHC class II receptor activity GO:0032395 8.62 HLA-DQA1 HLA-DQB1

Sources for Cervical Dystonia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....